A network meta-analysis of 27 randomized controlled trials shows that antiresorptive therapy does reduce the incidence of vertebral fracture in patients receiving oral glucocorticoids. Significant reductions in fracture rates were observed for only three agents: teriparatide and risedronate were both ranked 77% and etidronate was ranked 76% by SUCRA (surface under the cumulative ranking curve statistic). No agent significantly reduced nonvertebral fracture rates.